European Patent Office Grants Patent for ZyVersa Therapeutics' Lead Asset, Cholesterol Efflux Mediator VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease
Portfolio Pulse from Benzinga Newsdesk
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) has been granted a patent by the European Patent Office for its Phase 2a-ready Cholesterol Efflux Mediator VAR 200 for use in diabetic nephropathy/diabetic kidney disease. This development could potentially strengthen ZyVersa's position in the biopharmaceutical market.
July 07, 2023 | 11:39 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ZyVersa Therapeutics' stock could potentially see a positive impact due to the granting of a European patent for its drug VAR 200, which is ready for Phase 2a trials.
The granting of a patent for ZyVersa's drug VAR 200 strengthens the company's intellectual property rights and could potentially lead to increased investor confidence. This could result in a positive impact on the company's stock in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100